The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa
Open accessAbstract
TO THE EDITOR The skin fragility disorder, recessive dystrophic epidermolysis bullosa (RDEB) results from mutations in COL7A1, leading to reduced or absent type VII collagen (C7) and defective anchoring fibrils at the dermal–epidermal junction (Fine et al., 2014). Currently, there is no cure, and most individuals develop lifeshortening squamous cell carcinomas (Fine and Mellerio, 2009). RDEB also has a major health economic burden; wound dressings for a 10-year-old child can cost $680 per day (Kirkorian et al., 2014), which equates to 4$250,000 annually. Reported clinical trials of cell-based therapies for RDEB comprise intradermal allogeneic fibroblasts (Petrof et al., 2013; Venugopal et al., 2013), bone marrow transplantation (Wagner et al., 2010), intradermal bone marrow– derived mesenchymal stromal cells (BM-MSCs) (Conget et al., 2010), and intravenous BM-MSCs in RDEB adults (El-Darouti et al., 2013; abstract only). Ex vivo COL7A1 keratinocyte gene therapy is also being evaluated (Siprashvili et al., 2014). MSCs are heterogeneous cells that undergo self-renewal or differentiate into mesenchymal lineages (Caplan, 1991). MSCs also have non-progenitor functions in immune regulation, cell growth, and tissue repair (Phinney and Prockop, 2007; Chen et al., 2008). Nevertheless, healing is not associated with large numbers of therapeutic MSCs in injured tissues, suggesting that paracrine benefits may modulate inflammatory and immune responses (Baraniak and McDevitt, 2010). Our interest focuses on the potential of intravenous allogeneic BM-MSCs to help people living with RDEB. Ten children were included in the clinical trial and are detailed in Supplementary Table S1 online, with the trial protocol shown in Supplementary Figure S1 online. The trial was approved by the UK Medicines and Healthcare Products Regulatory Agency, with EudraCT number: 2012-001394-87; the UK National Research Ethics Committee London-Bloomsbury provided ethics approval (Ref:12/LO/1258), and the trial was registered prospectively with www. controlled-trials.com ISRCTN46615946. Written informed consent was obtained for each subject. Inclusion/exclusion criteria are presented in Supplementary Table S2 online, and study interventions are listed in Supplementary Table S3 online. Details of the BM-MSCs are provided in Supplementary Table S4 online. Each participant received three intravenous infusions of BM-MSCs (day 0, 7, and 28; each dose 1–3×10 cells kg) with no HLA matching or pre-conditioning. With regard to safety, there were 163 adverse events (AEs; Supplementary Tables S5–S7 online). Initially, two serious AEs, esophageal dilatation and skin infection, were reported but were subsequently downgraded (protocol version 4.0, 1 August 2014), as they were considered to be complications of RDEB and not the cells. Indeed, 127/163 (78%) of AEs were either unlikely or not related to the BM-MSCs. Concerning the severity of MSCrelated AEs, there were two severe events of DMSO odor, although odor was noted following 28/30 infusions (lasting up to 48 hours). Mild nausea occurred during two infusions, and abdominal pain and bradycardia were observed during two other infusions; all resolved within 15 minutes without treatment or hemodynamic compromise. No AEs resulted in discontinuation of MSCs. Laboratory assessments did not reveal any adverse impact of the BM-MSCs on renal, liver, or bone marrow function. Anti-C7 antibodies were detected by ELISA at baseline in 9/10 participants, but no sera bound to the dermal–epidermal junction by indirect immunofluorescence microscopy. Following MSCs, there were no changes in ELISA or indirect immunofluorescence microscopy data (Supplementary Table S8 online). Collectively, the tolerance data appear encouraging, although it should be noted that a zero event rate for a serious AE in just 10 patients is compatible with an upper 95% confidence interval of over 30%. With regard to secondary outcome measures, the data are summarized in Supplementary Table S9 online. Skin biopsies revealed no increase in C7 and no new anchoring fibrils at day 60. Fluorescence in situ hybridization analysis did not show donor-cell chimerism. Birmingham epidermolysis bullosa severity score (BEBSS) and global severity score questionnaires were completed for all the 10 participants (Supplementary Figures S2 and S3 online). Mean parentreported pain score was lower at 60 days than at baseline (mean difference: −5.5 points; 95% confidence interval (CI): LETTERS TO THE EDITOR
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, L., Tredget, E. E., Wu, P. Y. G., & Wu, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001886 · Cited by 1,610
Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
Wagner, J. E., Ishida-Yamamoto, A., McGrath, J. A., Hordinsky, M., Keene, D. R., Woodley, D. T., Chen, M., Riddle, M. J., Osborn, M. J., Lund, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910501 · Cited by 374
Self-citation
Cited by
Bardhan, A., Bruckner-Tuderman, L., Chapple, I. L. C., Fine, J.-D., Harper, N., Has, C., Magin, T. M., Marinkovich, M. P., Marshall, J. F., McGrath, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0210-0 · Cited by 455
Self-citationManufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use
Gimona, M., Pachler, K., Laner-Plamberger, S., Schallmoser, K., & Rohde, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061190 · Cited by 319
Metadata
- Authors
- Petrof, G., Lwin, S. M., Martinez-Queipo, M., Abdul-Wahab, A., Tso, S., Mellerio, J. E., Slaper-Cortenbach, I., Boelens, J. J., Tolar, J., Veys, P., Ofuya, M., Peacock, J. L., Martinez, A. E., & McGrath, J. A.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 135
- Issue
- 9
- Pages
- 2319-2321
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2064773694
- Cited by
- 170
- References
- 2
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.